Table 2 Summary of Adverse Events Occurring in Patients With and Without Allodynia
With Allodynia (n = 290) | Without Allodynia (n = 426) | |
|---|---|---|
AEs, n (%) | ||
≥ 1 AE | 185 (63.8) | 251 (58.9) |
Serious AE | 36 (12.4) | 39 (9.2) |
Discontinuation due to AE | 14 (4.8) | 18 (4.2) |
TRAEs, n (%) | ||
≥ 1 TRAE | 56 (19.3) | 75 (17.6) |
TRAEs occurring in ≥1% of either subgroup | ||
Neck pain | 15 (5.2) | 14 (3.3) |
Eyelid ptosis | 6 (2.1) | 12 (2.8) |
Musculoskeletal stiffness | 6 (2.1) | 11 (2.6) |
Headache | 6 (2.1) | 6 (1.4) |
Injection site pain | 5 (1.7) | 9 (2.1) |
Facial paresis | 4 (1.4) | 5 (1.2) |
Muscular weakness | 3 (1.0) | 7 (1.6) |
Migraine | 3 (1.0) | 4 (0.9) |
Injection site hematoma | 3 (1.0) | 1 (0.2) |
Muscle spasms | 3 (1.0) | 1 (0.2) |
Skin tightness | 1 (0.3) | 6 (1.4) |